It has been shown that MRD-directed IFN-α treatment was able to significantly decrease the risk of cumulative incidence of relapse and improve survival in MRD-positive AML patients post-HCT, compared to MRD patients with no intervention (77, 78). Here, IFNA1 is linked to acute myeloid leukemia.